A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
|Articles|June 1, 1998
The American Journal of Managed Care
- June 1998
- Volume 4
- Issue 6
Safety and Clinical Efficacy of Zileuton in Patients with Chronic Asthma
Advertisement
Articles in this issue
over 28 years ago
A Closer Look at Lower Back Painover 28 years ago
Rheumatoid Arthritis: Focus on Appropriate Drug TherapyAdvertisement
Related to this article
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
Symptom-tracking tools may improve awareness and patient-clinician communication but can also add stress.
Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.
The 2026 COA Payer Exchange and Innovation Summit began with a panel on AI and the ever-changing digital infrastructure in community oncology.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
Longer undetectable hepatitis D RNA on bulevirtide predicts durable suppression off therapy, but rebound and ALT flares rise, especially in cirrhosis.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Access and Innovation in North Carolina’s Research Triangle
3
An Odyssey of Symptoms, Setbacks, Treatments, and a Cure With CAR T-Cell Therapy
4
Biomarker-Driven Care Is Racing Ahead of the Systems Built to Support It
5